Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada.

"Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article."

"This study was supported by the Ontario Drug Policy Research Network (ODPRN), which is funded by grants from the Ontario Ministry of Health (MOH), and the Canadian Institutes of Health Research (CIHR, FRN 153070). This study also was supported by ICES, which is funded by an annual grant from the Ontario MOH. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI) and Cancer Care Ontario (CCO). The opinions, results, and conclusions reported are those of the authors and are independent from the data providers and funding sources. No endorsement by CIHI, CCO, ICES, CIHR, or the Ontario MOH is intended or should be inferred. The authors thank IMS Brogan Inc. for the use of their Drug Information Database. The authors thank Siyu Men for assistance with data analysis and Laura Robertson, Charlotte Munro, and Pat Messner, members of the Ontario Drug Policy Research Network Lived Experience Advisory Group, for their insight and feedback during this project."